Literature DB >> 17621814

Endoscopic septoplasty: revisitation of the technique, indications, and outcomes.

Brian J Chung1, Pete S Batra, Martin J Citardi, Donald C Lanza.   

Abstract

BACKGROUND: Septoplasty is a well-described surgical technique for management of nasal airway obstruction (NAO) and improved access for endoscopic sinus surgery (ESS). The advances in endoscopic techniques have facilitated endoscopic septoplasty (ES). The purpose of this study was to review the surgical technique, indications, and outcomes for ES.
METHODS: A retrospective review was conducted to identify patients undergoing ES between 1998 and 2005 at a tertiary care medical center. Demographic data, operative indications, adjunctive procedures, symptom outcome, and complications were recorded.
RESULTS: One hundred sixteen patients with a mean age of 47 years were identified. The male/female ratio was 1.2:1 and mean follow-up period was 13 months. Indications for ES included NAO (64.6%), access (34.5%), and facial pain (0.9%). The most common concomitant diagnoses included chronic rhinosinusitis (67.2%), allergic rhinitis (55.2%), sinonasal polyposis (34.5%), and turbinate hypertrophy (25.9%). Concomitant procedures performed included ESS (81.9%), turbinate reduction (44.8%), and rhinoplasty (4.3%). Among patients who underwent primary ES for NAO, 70% achieved resolution and 20% reported improvement of their nasal obstruction. Complications included transient dental pain/hypesthesia (4.3%), asymptomatic septal perforation (3.4%), synechiae formation (2.6%), epistaxis (0.9%), and septal hematoma (0.9%). Complication rates were similar for ES alone versus ES in conjunction with ESS.
CONCLUSION: ES represents a viable alternative to traditional headlight septoplasty with acceptable outcomes and complications. ES allows for enhanced visualization of the septal deviation with more focused flap dissection and resection of the offending cartilage and bone. Furthermore, the technique facilitates teaching endeavors through use of video monitors.

Entities:  

Mesh:

Year:  2007        PMID: 17621814     DOI: 10.2500/ajr.2007.21.3031

Source DB:  PubMed          Journal:  Am J Rhinol        ISSN: 1050-6586


  7 in total

1.  Endoscopic versus conventional septoplasty: objective/subjective data on 276 patients.

Authors:  Massimiliano Garzaro; Valeria Dell'Era; Giuseppe Riva; Luca Raimondo; Giancarlo Pecorari; Paolo Aluffi Valletti
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-03-20       Impact factor: 2.503

2.  Clinical application of suction-tube-assisted septal submucosal dissection for endoscopic septoplasty.

Authors:  Wen-Sen Lai; Yuan-Yung Lin; Cheng-Ping Shih; Hsin-Chien Chen; Pei-Lin Yang; Yueng-Hsiang Chu; Jinn-Moon Yang; Jih-Chin Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-11-04       Impact factor: 2.503

3.  Endoscopic Septoplasty-Two Handed Technique with Endoscope Holder: A Novel Approach.

Authors:  Mubarak M Khan; Sapna R Parab
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2016-05-28

4.  Intranasal trigeminal sensitivity: measurements before and after nasal surgery.

Authors:  M Scheibe; S Schulze; C A Mueller; B Schuster; Thomas Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-09       Impact factor: 2.503

5.  Endoscopic Septoplasty with Limited Two-line Resection: Minimally Invasive Surgery for Septal Deviation.

Authors:  Ke-Qing Zhao; Shi-Lei Pu; Hong-Meng Yu
Journal:  J Vis Exp       Date:  2018-06-20       Impact factor: 1.355

6.  Endoscopic Septoplasty: A Retrospective Analysis of 415 Cases.

Authors:  Shreeya V Kulkarni; Vinay P Kulkarni; Kiran Burse; Manu Bharath; Chaitanya Bharadwaj; Vandana Sancheti
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2015-07-02

7.  A modified combined transseptal/transnasal binostril approach for pituitary lesions in patients with a narrow nasal space: technical note.

Authors:  Mitsuhiro Takemura; Yasunori Fujimoto; Taisuke Kobayashi; Masahiro Komori; Aldo C Stamm; Eduardo Vellutini; Pedro Mariani; Yu Kawanishi; Keiji Shimizu
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-07-28       Impact factor: 1.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.